I

Iovance Biotherapeutics
D

IOVA

5.90500
USD
-0.08
(-1.34%)
مفتوح الان
حجم التداول
107,199
الربح لكل سهم
-1
العائد الربحي
-
P/E
-4
حجم السوق
1,801,254,469
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ADPT
    0.06000
    (0.75%)
    8.07000 USD
    A
    ALLO
    -0.04000
    (-2.08%)
    1.88500 USD
    A
    ASTS
    -3.470
    (-15.41%)
    19.050 USD
    C
    CRSP
    -0.660
    (-1.49%)
    43.540 USD
    F
    FATE
    -0.00500
    (-0.37%)
    1.34000 USD
    MRNA
    MRNA
    0.390
    (1.01%)
    38.880 USD
    S
    SLDB
    -0.05000
    (-1.60%)
    3.08000 USD
    المزيد
الأخبار
المقالات

العنوان: Iovance Biotherapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.